CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics


Today's Latest Price: $80.68 USD

0.80 (-0.98%)

Updated Jan 21 4:00pm

Add CSTL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

CSTL Stock Summary

  • With a one year PEG ratio of 0.64, Castle Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.04% of US stocks.
  • Castle Biosciences Inc's stock had its IPO on July 25, 2019, making it an older stock than just 1.67% of US equities in our set.
  • The price/operating cash flow metric for Castle Biosciences Inc is higher than 94.98% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to CSTL, based on their financial statements, market capitalization, and price volatility, are AXTI, PING, MLAB, KRMD, and AYX.
  • CSTL's SEC filings can be seen here. And to visit Castle Biosciences Inc's official web site, go to

CSTL Stock Price Chart Interactive Chart >

Price chart for CSTL

CSTL Price/Volume Stats

Current price $80.68 52-week high $84.00
Prev. close $81.48 52-week low $21.01
Day low $78.84 Volume 191,119
Day high $83.56 Avg. volume 242,745
50-day MA $61.46 Dividend yield N/A
200-day MA $46.69 Market Cap 1.63B


Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.

CSTL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$80.68$177.96 118%

Below please find a table outlining a discounted cash flow forecast for CSTL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Castle Biosciences Inc ranked in the 68th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Castle Biosciences Inc, consider:

  • As a business, CSTL is generating more cash flow than merely 15.44% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.66% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Castle Biosciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

CRHM, HCSG, LH, ABBV, and SGRY can be thought of as valuation peers to CSTL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

CSTL Latest News Stream

Event/Time News Detail
Loading, please wait...

CSTL Latest Social Stream

Loading social stream, please wait...

View Full CSTL Social Stream

Latest CSTL News From Around the Web

Below are the latest news stories about Castle Biosciences Inc that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference.

Yahoo | January 20, 2021

Castle Biosciences (CSTL) Investor Presentation - Slideshow

The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 19, 2021

Castle Biosciences provides Q4 and FY20 update

Castle Biosciences ([[CSTL]] -5.7%) announced preliminary performance results for 4Q20 and FY20.Delivered 18,185 gene expression profile test reports in 2020.Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020. Since the effective date, more than 90% of Medicare beneficiaries whose clinicians order DecisionDx-Melanoma as part...

Seeking Alpha | January 13, 2021

Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.

Business Wire | January 4, 2021

Castle Biosciences Announces Early Repayment of Debt

Castle today announced it prepaid in full its outstanding term loan facility.

Yahoo | December 22, 2020

Read More 'CSTL' Stories Here

CSTL Price Returns

1-mo 11.14%
3-mo 55.63%
6-mo 106.66%
1-year 151.18%
3-year N/A
5-year N/A
YTD 20.15%
2020 95.37%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8307 seconds.